Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats

✍ Scribed by Rui Zhao; Wen-Zhen Shi; Yong-Mei Zhang; San-Hua Fang; Er-Qing Wei

• Book ID: 118111484
• Publisher: Pharmaceutical Press
• Year: 2011
• Tongue: English
• Weight: 579 KB
• Volume: 63
• Category: Article
• ISSN: 2042-7158
• DOI: 10.1111/j.2042-7158.2010.01238.x

✦ Synopsis

Abstract

Objectives

Previously we demonstrated the neuroprotective effect of montelukast, a cysteinyl leukotriene receptor-1 (CysLT1) antagonist, on acute brain injury after focal cerebral ischaemia in mice. In this study, we have determined its effect on chronic brain injury after focal cerebral ischaemia in mice and rats.

Methods

After transient focal cerebral ischaemia was induced by middle cerebral artery occlusion, montelukast was intraperitoneally injected in mice or orally administered to rats for five days. Behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss were determined to evaluate brain lesions.

Key findings

Montelukast (0.1 mg/kg) attenuated behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss in mice, which was similar to pranlukast, another CysLT1 receptor antagonist. Oral montelukast (0.5 mg/kg) was effective in rats and was more effective than edaravone, a free radical scavenger.

Conclusion

Montelukast protected mice and rats against chronic brain injury after focal cerebral ischaemia, supporting the therapeutic potential of CysLT1 receptor antagonists.